Because activation of VEGFR-2 plays an important role in tumor angiogenesis, clinical interest in monitoring plasma sVEGFR-2 levels in cancer patients has focused on its potential use as a surrogate biomarker for disease progression as well as assessing efficacy/activity of antiangiogenic drugs particularly those that target VEGF or VEGFR-2 [9, 27]. The gene discussed is KDR; the disease is cancer.